February 18, 2025
Scopolamine API Market

Pharmaceutical Scopolamine API Market Driven By Growing Non-Intravenous Anticholinergic Usage

Scopolamine belongs to the group of medicines known as anticholinergics. As an anticholinergic agent, scopolamine is used to treat and prevent nausea, vomiting, and motion sickness. It works by blocking muscarinic acetylcholine receptors in the brain to decrease the neurotransmitter acetylcholine’s effects. Scopolamine is commonly administered through transdermal patches, gel, cream, or injections and effective in treating post-operative nausea, vomiting, dizziness associated with motion sickness. The global scopolamine API market has witnessed strong growth as an alternative to intravenous delivery of anticholinergic drug due to its needle-free and painless mode of usage.

The global Scopolamine API Market is estimated to be valued at US$ 308.49 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Transdermal administration of Scopolamine has gained wide acceptance owing to the avoidance of first-pass metabolism by the liver which allows for more efficient absorption of the drug. Major pharmaceutical companies are focusing on developing transdermal patches containing precise doses of scopolamine to expand market presence. Further, the rising popularity of scopolamine patches over oral medications and injections amid growing preference for needle-free dosage forms among patients is a key trend fueling the scopolamine API market over the forecast period.

Porter’s Analysis

Threat of new entrants: The threat of new entrants into the Scopolamine API market is moderate as it requires large capital investment to set up manufacturing facilities.

Bargaining power of buyers: The bargaining power of buyers in the Scopolamine API market is high due to the availability of several products to treat motion sickness.

Bargaining power of suppliers: Suppliers have moderate bargaining power due to the availability of substitutes.

Threat of new substitutes: The threat of substitutes is moderate as there are alternative pharmaceutical products available for motion sickness.

Competitive rivalry: Competition is high among the existing players operating in the Scopolamine API market.

Key Takeaways

The global Scopolamine API Market Growth is expected to witness high growth over the forecast period of 2023 to 2030. The global Scopolamine API Market is estimated to be valued at US$ 308.49 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030.

Regional analysis

The Asia Pacific region is anticipated to account for the largest share of the global Scopolamine API market during the forecast period. China is the world’s largest producer and consumer of Scopolamine API. Growing pharmaceutical industry and increasing healthcare expenditure are estimated to boost the regional market growth.

Key players

Key players operating in the Scopolamine API market are Daikin Industries Limited, Viessmann Group, NIBE Group, Danfoss Group Global, Stiebel Eltron Group, Mitsubishi Electric Corporation, United Technologies Corporation, Panasonic Corporation, Glen Dimplex Group. Competition among these players is intense.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Money Singh
+ posts

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. 

Money Singh

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. 

View all posts by Money Singh →